International Clinical Trial: Clinical Trial of CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Acute Respiratory Distress Syndrome

Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07892950) titled 'Clinical Trial of CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Acute Respiratory Distress Syndrome' on Oct. 19.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: GuangZhou Cellgenes Biotechnology Co., Ltd.

Condition: Acute Respiratory Distress Syndrome (ARDS)

Intervention: Biological: CG-BM1 Biological: CG-BM1

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: January 4, 2023

Target Sample Size: 15

Cou...